JP2009215299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009215299A5 JP2009215299A5 JP2009092074A JP2009092074A JP2009215299A5 JP 2009215299 A5 JP2009215299 A5 JP 2009215299A5 JP 2009092074 A JP2009092074 A JP 2009092074A JP 2009092074 A JP2009092074 A JP 2009092074A JP 2009215299 A5 JP2009215299 A5 JP 2009215299A5
- Authority
- JP
- Japan
- Prior art keywords
- igf
- composition
- binding
- deoxycholamine
- gluconamidopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 42
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 41
- 238000000034 method Methods 0.000 claims 40
- 239000000203 mixture Substances 0.000 claims 17
- 239000000556 agonist Substances 0.000 claims 12
- 239000013078 crystal Substances 0.000 claims 8
- 238000002425 crystallisation Methods 0.000 claims 6
- 230000008025 crystallization Effects 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 5
- 239000001509 sodium citrate Substances 0.000 claims 5
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims 4
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims 4
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 claims 4
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 238000009792 diffusion process Methods 0.000 claims 3
- 208000037824 growth disorder Diseases 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 230000010807 negative regulation of binding Effects 0.000 claims 3
- 230000001376 precipitating effect Effects 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 238000012286 ELISA Assay Methods 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 2
- 235000011130 ammonium sulphate Nutrition 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- SAMYCKUDTNLASP-UHFFFAOYSA-N hexane-2,2-diol Chemical compound CCCCC(C)(O)O SAMYCKUDTNLASP-UHFFFAOYSA-N 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 208000018360 neuromuscular disease Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 241001515965 unidentified phage Species 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 206010007733 Catabolic state Diseases 0.000 claims 1
- 102100038796 E3 ubiquitin-protein ligase TRIM13 Human genes 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 101000664589 Homo sapiens E3 ubiquitin-protein ligase TRIM13 Proteins 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 208000006302 Laron syndrome Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000006227 SHORT syndrome Diseases 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000011032 Werner Syndrome Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 208000016253 exhaustion Diseases 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 102000044162 human IGF1 Human genes 0.000 claims 1
- 230000003345 hyperglycaemic effect Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 claims 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 claims 1
- 201000006334 interstitial nephritis Diseases 0.000 claims 1
- 230000001678 irradiating effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26797701P | 2001-02-09 | 2001-02-09 | |
| US28707201P | 2001-04-27 | 2001-04-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002564956A Division JP4489352B2 (ja) | 2001-02-09 | 2002-02-01 | Ｉｇｆ−１の結晶化 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009215299A JP2009215299A (ja) | 2009-09-24 |
| JP2009215299A5 true JP2009215299A5 (https=) | 2010-05-20 |
Family
ID=26952796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002564956A Expired - Fee Related JP4489352B2 (ja) | 2001-02-09 | 2002-02-01 | Ｉｇｆ−１の結晶化 |
| JP2009092074A Withdrawn JP2009215299A (ja) | 2001-02-09 | 2009-04-06 | Ｉｇｆ−１の結晶化 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002564956A Expired - Fee Related JP4489352B2 (ja) | 2001-02-09 | 2002-02-01 | Ｉｇｆ−１の結晶化 |
Country Status (19)
| Country | Link |
|---|---|
| US (8) | US7084240B2 (https=) |
| EP (3) | EP1358209B1 (https=) |
| JP (2) | JP4489352B2 (https=) |
| KR (1) | KR100872613B1 (https=) |
| CN (1) | CN100439397C (https=) |
| AT (2) | ATE349469T1 (https=) |
| AU (1) | AU2002255508B2 (https=) |
| BR (1) | BR0207422A (https=) |
| CA (1) | CA2431033A1 (https=) |
| DE (3) | DE60233359D1 (https=) |
| DK (2) | DK1358209T3 (https=) |
| ES (2) | ES2331150T3 (https=) |
| HU (1) | HUP0500733A3 (https=) |
| IL (2) | IL156435A0 (https=) |
| MX (1) | MXPA03007042A (https=) |
| NZ (3) | NZ526672A (https=) |
| PL (1) | PL374181A1 (https=) |
| WO (1) | WO2002064627A2 (https=) |
| ZA (1) | ZA200304900B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072780A2 (en) * | 2001-03-14 | 2002-09-19 | Genentech, Inc. | Igf antagonist peptides |
| US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| US6914049B2 (en) | 2001-09-18 | 2005-07-05 | Bioexpertise, Llc | IGF-binding protein-derived peptide or small molecule |
| US6861406B2 (en) * | 2001-09-18 | 2005-03-01 | Bioexpertise, Llc | IGF-binding protein-derived peptide |
| EP1627323A4 (en) * | 2003-05-06 | 2008-04-09 | New Century Pharmaceuticals | ALBUMIN FIXATION SITES FOR EVALUATING DRUG INTERACTIONS OR THE DEVELOPMENT OF MEDICAMENTS BASED ON THEIR ALBUMIN BINDING PROPERTIES |
| US20070043509A1 (en) * | 2003-11-03 | 2007-02-22 | Carter Daniel C | Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties |
| CN101829319A (zh) | 2003-12-08 | 2010-09-15 | Cpex药品公司 | 用于胰岛素治疗的药用组合物及方法 |
| WO2006001911A2 (en) * | 2004-05-06 | 2006-01-05 | Genentech, Inc. | Crystal structure of the hepatocyte growth factor beta chain and methods of use |
| WO2005108424A1 (en) * | 2004-05-06 | 2005-11-17 | Genentech, Inc. | Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use |
| RU2527893C2 (ru) * | 2004-07-19 | 2014-09-10 | Биокон Лимитед | Инсулин-олигомерные конъюгаты, их препараты и применения |
| JP2008514240A (ja) * | 2004-10-01 | 2008-05-08 | インヴィトロジェン コーポレーション | 生体分子のインビトロ合成用の供給バッファー、系、及び方法 |
| US7556776B2 (en) * | 2005-09-08 | 2009-07-07 | President And Fellows Of Harvard College | Microfluidic manipulation of fluids and reactions |
| CA2689549A1 (en) * | 2007-06-08 | 2008-12-18 | Massachusetts Institute Of Technology | Igf for the treatment of rett syndrome and synaptic disorders |
| WO2009026172A2 (en) * | 2007-08-17 | 2009-02-26 | The Regents Of The University Of California | New approach for designing diabetes drugs |
| CN101139391B (zh) * | 2007-08-21 | 2012-07-25 | 陈志南 | Cd147胞外区晶体结构及应用 |
| US9664619B2 (en) | 2008-04-28 | 2017-05-30 | President And Fellows Of Harvard College | Microfluidic device for storage and well-defined arrangement of droplets |
| WO2011011072A2 (en) * | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59 |
| WO2011011071A2 (en) * | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) |
| WO2011047204A1 (en) * | 2009-10-14 | 2011-04-21 | Mount Sinai School Of Medicine | Method of treating memory disorders and enhancing memory using igf-ii compounds |
| US20150119394A1 (en) * | 2012-03-28 | 2015-04-30 | Merck Sharp & Dohme Corp. | Insulin-Like Growth Factor-1 Receptor Inhibitors |
| KR101711584B1 (ko) * | 2012-12-18 | 2017-03-02 | 재단법인 의약바이오컨버젼스연구단 | 변형된 eprs 단백질의 결정 구조 및 이의 결정화 방법 |
| ES2872998T3 (es) | 2013-12-19 | 2021-11-03 | Puretein Bioscience Llc | Procedimientos de tratamiento de animales |
| US12324827B2 (en) | 2019-09-09 | 2025-06-10 | The University Of Chicago | Combination therapy for the treatment of migraines |
| WO2021248160A1 (en) * | 2020-06-01 | 2021-12-09 | Loma Linda University Health | Methods of treatment of a cytokine storm |
| WO2025259950A1 (en) * | 2024-06-14 | 2025-12-18 | Cz Biohub Sf, Llc | Genetically encoded lysosome targeting chimeras for cell-mediated delivery |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US589867A (en) * | 1897-09-14 | Clothes-line hanger | ||
| US577276A (en) * | 1897-02-16 | Quarter-saver iv | ||
| US4672108A (en) * | 1981-12-07 | 1987-06-09 | Hoffmann-La Roche Inc. | Crystalline human leukocyte interferon |
| DE3327709A1 (de) * | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
| ATE81779T1 (de) * | 1985-08-22 | 1992-11-15 | Gropep Pty Ltd | Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren. |
| DE3717370A1 (de) * | 1987-05-22 | 1988-12-01 | Hoechst Ag | Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus |
| US4833233A (en) * | 1987-08-20 | 1989-05-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Human serum albumin crystals and method of preparation |
| SE8703625D0 (sv) | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
| US4876242A (en) * | 1987-09-21 | 1989-10-24 | Merck & Co., Inc. | Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast |
| ATE116335T1 (de) * | 1987-12-24 | 1995-01-15 | Gropep Pty Ltd | Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2). |
| US5470828A (en) * | 1987-12-24 | 1995-11-28 | Gropep Pty. Ltd. | Peptide analogs of insulin-like growth factor II |
| US4988675A (en) * | 1988-02-05 | 1991-01-29 | Ciba-Geigy Corporation | Method for preventing secondary effects |
| EP0327503B1 (en) * | 1988-02-05 | 1993-03-10 | Ciba-Geigy Ag | Use of igf i in the manufacture of a medicament for the treatment of renal diseases |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| GB8920381D0 (en) | 1989-09-08 | 1989-10-25 | Greater Glasgow Health Board | Treatment of insulin-resistant diabetes |
| US5028224A (en) * | 1990-01-09 | 1991-07-02 | Kimberly-Clark Corporation | Apparatus for intermittently depositing particulate material in a substrate |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US5681814A (en) | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
| US5374620A (en) * | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
| SE9100099D0 (sv) | 1991-01-11 | 1991-01-11 | Kabi Pharmacia Ab | Use of growth factor |
| US5187151A (en) * | 1991-02-12 | 1993-02-16 | Genentech, Inc. | Use of binding protein with igf-i as an anabolic growth promoting agent |
| US5202119A (en) * | 1991-06-28 | 1993-04-13 | Genentech, Inc. | Method of stimulating immune response |
| EP0597033B1 (en) * | 1991-08-01 | 1997-04-09 | Genentech, Inc. | Igf-1 to improve the neural condition |
| US5126314A (en) * | 1991-09-06 | 1992-06-30 | Eastman Kodak Company | Mixture of dyes for black dye donor for thermal color proofing |
| US6310040B1 (en) | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
| WO1993023067A1 (en) | 1992-05-08 | 1993-11-25 | Thomas Jefferson University | Igf-1 analogs |
| SE9201573D0 (sv) | 1992-05-19 | 1992-05-19 | Kabi Pharmacia Ab | Use of igf-1 |
| EP0668914B1 (en) | 1992-06-09 | 2000-08-16 | Chiron Corporation | Crystallization of m-csf |
| HU217543B (hu) * | 1992-06-12 | 2000-02-28 | Albert Einstein College Of Medicine Of Yeshiva University | Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények |
| NZ255461A (en) | 1992-08-20 | 1996-12-20 | Biotechnology & Biolog Science | Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity |
| US5273961A (en) * | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
| CA2132871A1 (en) | 1993-01-25 | 1994-08-04 | Alan C. Moses | Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties |
| DK72793D0 (da) * | 1993-06-21 | 1993-06-21 | Novo Nordisk As | Nyt produkt |
| US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
| US5407810A (en) | 1993-08-20 | 1995-04-18 | Genentech, Inc. | Aqueous multiple-phase isolation of polypeptide |
| US5504188A (en) * | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
| US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| SE9402370D0 (sv) | 1994-07-04 | 1994-07-04 | Pharmacia Ab | Use of IGF-I |
| US5597893A (en) * | 1994-10-31 | 1997-01-28 | Eli Lilly And Company | Preparation of stable insulin analog crystals |
| YU18596A (sh) * | 1995-03-31 | 1998-07-10 | Eli Lilly And Company | Analogne formulacije monomernog insulina |
| SE9501472D0 (sv) | 1995-04-21 | 1995-04-21 | Pharmacia Ab | Truncated IGF-I |
| WO1997000895A1 (en) | 1995-06-22 | 1997-01-09 | Biogen, Inc. | Crystals of fragments of cd40 ligand and their use |
| US5948751A (en) * | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
| JP3417230B2 (ja) * | 1996-09-25 | 2003-06-16 | 信越化学工業株式会社 | 型取り母型用光硬化性液状シリコーンゴム組成物 |
| US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| US5898028A (en) * | 1997-03-20 | 1999-04-27 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
| US6121416A (en) * | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| JP2002510321A (ja) | 1997-07-03 | 2002-04-02 | スミスクライン・ビーチャム・コーポレイション | 抗−第ＩＸ因子 Ｆａｂフラグメントの結晶構造およびペプチド模倣物デザインのための使用方法 |
| US5876242A (en) * | 1997-07-21 | 1999-03-02 | Williams; Hugh D. | Remote battery extension apparatus |
| NZ506091A (en) | 1998-01-21 | 2003-07-25 | Brigham & Womens Hospital | Circulating insulin-like growth factor-i and prostate cancer risk |
| WO2000023469A2 (en) | 1998-10-16 | 2000-04-27 | Musc Foundation For Research Development | Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof |
| EP1383793B1 (en) | 2000-03-29 | 2011-10-19 | DGI BioTechnologies, L.L.C. | Insulin and igf-1 receptor agonists and antagonists |
| CA2449290A1 (en) | 2001-06-07 | 2002-12-12 | F. Hoffmann-La Roche Ag | Mutants of igf binding proteins and methods of production of antagonists thereof |
| US20040137518A1 (en) * | 2002-01-31 | 2004-07-15 | Lambert Millard Hurst | CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME |
| JP3680801B2 (ja) * | 2002-02-27 | 2005-08-10 | 株式会社デンソー | 回転電機の巻線接合方法 |
-
2002
- 2002-02-01 CN CNB028047079A patent/CN100439397C/zh not_active Expired - Fee Related
- 2002-02-01 DE DE60233359T patent/DE60233359D1/de not_active Expired - Lifetime
- 2002-02-01 IL IL15643502A patent/IL156435A0/xx unknown
- 2002-02-01 EP EP02724908A patent/EP1358209B1/en not_active Expired - Lifetime
- 2002-02-01 PL PL02374181A patent/PL374181A1/xx not_active Application Discontinuation
- 2002-02-01 DK DK02724908T patent/DK1358209T3/da active
- 2002-02-01 EP EP06026832A patent/EP1772464B1/en not_active Expired - Lifetime
- 2002-02-01 BR BR0207422-2A patent/BR0207422A/pt not_active Application Discontinuation
- 2002-02-01 AU AU2002255508A patent/AU2002255508B2/en not_active Ceased
- 2002-02-01 EP EP06026833A patent/EP1801120A1/en not_active Withdrawn
- 2002-02-01 US US10/066,009 patent/US7084240B2/en not_active Expired - Fee Related
- 2002-02-01 NZ NZ526672A patent/NZ526672A/en not_active IP Right Cessation
- 2002-02-01 CA CA002431033A patent/CA2431033A1/en not_active Abandoned
- 2002-02-01 NZ NZ548359A patent/NZ548359A/en not_active IP Right Cessation
- 2002-02-01 DE DE60217066T patent/DE60217066T4/de not_active Expired - Lifetime
- 2002-02-01 KR KR1020037010465A patent/KR100872613B1/ko not_active Expired - Fee Related
- 2002-02-01 DK DK06026832T patent/DK1772464T3/da active
- 2002-02-01 AT AT02724908T patent/ATE349469T1/de active
- 2002-02-01 JP JP2002564956A patent/JP4489352B2/ja not_active Expired - Fee Related
- 2002-02-01 DE DE60217066A patent/DE60217066D1/de not_active Expired - Lifetime
- 2002-02-01 AT AT06026832T patent/ATE439378T1/de active
- 2002-02-01 ES ES06026832T patent/ES2331150T3/es not_active Expired - Lifetime
- 2002-02-01 WO PCT/US2002/003156 patent/WO2002064627A2/en not_active Ceased
- 2002-02-01 ES ES02724908T patent/ES2278020T3/es not_active Expired - Lifetime
- 2002-02-01 MX MXPA03007042A patent/MXPA03007042A/es active IP Right Grant
- 2002-02-01 HU HU0500733A patent/HUP0500733A3/hu unknown
- 2002-02-01 NZ NZ548358A patent/NZ548358A/en not_active IP Right Cessation
-
2003
- 2003-06-12 IL IL156435A patent/IL156435A/en not_active IP Right Cessation
- 2003-06-24 ZA ZA2003/04900A patent/ZA200304900B/en unknown
-
2005
- 2005-04-14 US US11/107,672 patent/US7238658B2/en not_active Expired - Fee Related
-
2006
- 2006-06-20 US US11/472,121 patent/US7354769B2/en not_active Expired - Fee Related
- 2006-06-20 US US11/471,912 patent/US7297763B2/en not_active Expired - Fee Related
- 2006-06-20 US US11/472,122 patent/US20060270839A1/en not_active Abandoned
- 2006-06-20 US US11/471,897 patent/US7433788B2/en not_active Expired - Fee Related
- 2006-06-20 US US11/471,896 patent/US7596455B2/en not_active Expired - Fee Related
- 2006-06-20 US US11/471,895 patent/US20060276397A1/en not_active Abandoned
-
2009
- 2009-04-06 JP JP2009092074A patent/JP2009215299A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009215299A5 (https=) | ||
| CN103180734B (zh) | 稳定gpcr的功能构象状态的蛋白结合结构域及其用途 | |
| KR100872613B1 (ko) | Ｉｇｆ-1의 결정화 | |
| US8507209B2 (en) | Biomarkers | |
| US20090117662A1 (en) | Mutants of IGF Binding Proteins and Methods of Production of Antagonists Thereof | |
| AU2002255508A1 (en) | Crystallization of IGF-1 | |
| CN109134614A (zh) | Tfpi抑制剂及其使用方法 | |
| CN107043418A (zh) | 生物标记物 | |
| Denley et al. | Structural and functional characteristics of the Val44Met IGF-I missense mutation: correlation with effects on growth and development | |
| JP2006525782A5 (https=) | ||
| JP2006526384A5 (https=) | ||
| HK1060138B (en) | Crystallization of igf-1 |